Full Title: Microbiological Attributes, Specifications and Risk Assessment of Culture-based Therapeutic Products A major challenge with emerging heterogeneous, live culture-based products is setting consistent, risk-based microbial specifications to protect the recipients of these product from potential microbial infection. A review of the literature and the published regulatory requirements demonstrates a lack of consensus as to donor and/or product infectious disease screening that may inevitably harm patients along with increased costs and delayed product availability. This presentation addresses the microbiological attributes, specifications, screening methods, and risk assessment of these unique products that contain live microbiological cultures, include probiotics, fecal microbiota transplantations, fecal-derived consortium cultures and therapeutic bacteriophage products and makes recommendations as to the path forward.

Hora

15:00 - 16:00 hs GMT+1

Organizador

BioPharma Asia Magazine
Compartir
Enviar a un amigo
Mi email *
Email destinatario *
Comentario *
Repite estos números *
Control de seguridad
Abril / 2021 1395 webinars
Lunes
Martes
Miércoles
Jueves
Viernes
Sábado
Domingo
Lun 29 de Abril de 2021
Mar 30 de Abril de 2021
Mié 31 de Abril de 2021
Jue 01 de Abril de 2021
Vie 02 de Abril de 2021
Sáb 03 de Abril de 2021
Dom 04 de Abril de 2021
Lun 05 de Abril de 2021
Mar 06 de Abril de 2021
Mié 07 de Abril de 2021
Jue 08 de Abril de 2021
Vie 09 de Abril de 2021
Sáb 10 de Abril de 2021
Dom 11 de Abril de 2021
Lun 12 de Abril de 2021
Mar 13 de Abril de 2021
Mié 14 de Abril de 2021